We’re thrilled to share an electrifying update on the Abacus FCF Small Cap Leaders ETF (ABLS): our largest holding, Corcept Therapeutics ($CORT), has delivered a game-changing performance. Today, $CORT surged over 100% following the announcement of successful Phase 3 trial results for Relacorilant, a promising treatment for Cushing’s syndrome. This milestone not only propelled $CORT’s weighting in ABLS from 6% to 12% but also drove a remarkable 6% outperformance of ABLS against the Russell 2000 in a single day.
Key Highlights:
- Massive Surge: $CORT’s stock skyrocketed over 100% after the Phase 3 trial met its endpoints, marking a significant clinical victory.
- Portfolio Impact: This rally boosted ABLS’s performance, outpacing the Russell 2000 by 6% alone.
- Top Holding Strength: Entering the day as ABLS’s largest position at 6%, $CORT now commands a 12% weight in the ETF.
Why It Matters:
This isn’t just a win for $CORT—it’s a resounding validation of our Free Cash Flow Small Cap Leaders strategy. At Abacus FCF Advisors, we focus on identifying companies with strong fundamentals and the potential for outsized returns. Today’s news reinforces that thesis: $CORT’s clinical success highlights how our approach can generate material alpha, as it has in past cycles. Looking ahead, with regulatory milestones on the horizon, this could be just the beginning of a sustained rally for $CORT and, by extension, ABLS investors.
For more details on $CORT’s breakthrough, check out this article: Corcept Therapeutics Stock Soars After Successful Phase 3 Trial.
Stay tuned as we continue to navigate the small-cap landscape, delivering value through disciplined, cash-flow-driven investing.
The fund’s investment objectives, risks, charges and expenses must be considered carefully before investing. The prospectus contains this and other important information about investment company, and it may be obtained by calling +1 (800) 617-0004. Read it carefully before investing.
Fund holdings and/or sector allocations are subject to change at any time and are not recommendations to buy or sell any security.
**The 30-Day SEC Yield is computed under an SEC standardized formula based on net income earned over the past 30 days.
There is no guarantee that ABLS will achieve its investment objective. Investing involves risk, including the possible loss of principal. Because the Fund is an ETF (rather than a mutual fund), shares are bought and sold at market price (not NAV), may trade at a discount or premium to NAV, and are not individually redeemable. Owners of the shares may acquire those shares from the Fund and tender those shares for redemption to the Fund in Creation Unit aggregations only, consisting of 25,000 shares. Brokerage commissions will reduce returns. Investments in the Fund include risks associated with small-and mid-cap securities, which involve limited liquidity and greater volatility than large-cap securities.
Passive funds that seek to track an index may hold the component securities of the underlying index regardless of the current or projected performance of a specific security or relevant market as a whole, which could cause the Fund returns to be lower than if the Fund employed an active strategy. The performance of the Fund may diverge from that of its Index.
The Russell 2000 tracks the roughly 2000 securities that are considered to be US small cap companies. The Russell 2000 serves as an important benchmark when investors want to track their small cap performances versus other sized companies.
Free Cash Flow (FCF) represents the cash that a company is able to generate after accounting for capital expenditures.
Market Price: The current price at which shares are bought and sold. Market returns are based upon last trade price. NAV: The dollar value of a single share, based on the value of the underlying assets of the fund minus its liabilities, divided by the number of shares outstanding. Calculated at the end of each business day.
Opinions expressed are subject to change, are not guaranteed, and should not be considered investment advice.
The FCF ETFs are distributed by Quasar Distributors, LLC.
© FCF Funds. All Rights Reserved.
